Bausch Health/$BHC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bausch Health

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Ticker

$BHC

Primary listing

NYSE

Industry

Pharmaceuticals

Headquarters

Laval, Canada

Employees

20,700

ISIN

CA0717341071

Bausch Health Metrics

BasicAdvanced
$2.4B
-
-$0.11
0.43
-

What the Analysts think about Bausch Health

Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.

Bulls say / Bears say

Bausch Health's Salix segment reported a 9% year-over-year revenue increase in Q1 2025, indicating strong performance in its gastroenterology business. (Investing.com)
The company launched the Fraxel FTX™, an advanced skin resurfacing technology, at the ASLMS 2025 Conference, potentially expanding its aesthetic product portfolio. (StockTitan)
Bausch Health received Health Canada clearance for the Thermage FLX system, enhancing its presence in the non-invasive skin tightening market. (StockTitan)
Bausch Health reported a Q1 2025 loss per share of $0.17, missing analyst expectations of $0.69 EPS, raising concerns about profitability. (Investing.com)
The company has a high leverage ratio of approximately 7 times, with upcoming debt maturities in 2025-2026, posing solvency risks. (Markets Insider)
Bausch + Lomb initiated a voluntary recall of certain intraocular lenses due to reported complications, potentially impacting brand reputation and financial performance. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

Bausch Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bausch Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BHC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs